JP2008544960A5 - - Google Patents

Download PDF

Info

Publication number
JP2008544960A5
JP2008544960A5 JP2008511317A JP2008511317A JP2008544960A5 JP 2008544960 A5 JP2008544960 A5 JP 2008544960A5 JP 2008511317 A JP2008511317 A JP 2008511317A JP 2008511317 A JP2008511317 A JP 2008511317A JP 2008544960 A5 JP2008544960 A5 JP 2008544960A5
Authority
JP
Japan
Prior art keywords
tweak
tnf
composition
blocker
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008511317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008544960A (ja
JP5339901B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/018077 external-priority patent/WO2006122187A2/en
Publication of JP2008544960A publication Critical patent/JP2008544960A/ja
Publication of JP2008544960A5 publication Critical patent/JP2008544960A5/ja
Application granted granted Critical
Publication of JP5339901B2 publication Critical patent/JP5339901B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008511317A 2005-05-10 2006-05-10 炎症傷害の処置および評価 Expired - Fee Related JP5339901B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67951805P 2005-05-10 2005-05-10
US60/679,518 2005-05-10
PCT/US2006/018077 WO2006122187A2 (en) 2005-05-10 2006-05-10 Treating and evaluating inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009114031A Division JP2009179632A (ja) 2005-05-10 2009-05-08 炎症傷害の処置および評価

Publications (3)

Publication Number Publication Date
JP2008544960A JP2008544960A (ja) 2008-12-11
JP2008544960A5 true JP2008544960A5 (cg-RX-API-DMAC7.html) 2009-06-25
JP5339901B2 JP5339901B2 (ja) 2013-11-13

Family

ID=37397272

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008511317A Expired - Fee Related JP5339901B2 (ja) 2005-05-10 2006-05-10 炎症傷害の処置および評価
JP2009114031A Withdrawn JP2009179632A (ja) 2005-05-10 2009-05-08 炎症傷害の処置および評価
JP2012231580A Expired - Fee Related JP5926162B2 (ja) 2005-05-10 2012-10-19 炎症傷害の処置および評価
JP2014127923A Withdrawn JP2014185171A (ja) 2005-05-10 2014-06-23 炎症傷害の処置および評価

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009114031A Withdrawn JP2009179632A (ja) 2005-05-10 2009-05-08 炎症傷害の処置および評価
JP2012231580A Expired - Fee Related JP5926162B2 (ja) 2005-05-10 2012-10-19 炎症傷害の処置および評価
JP2014127923A Withdrawn JP2014185171A (ja) 2005-05-10 2014-06-23 炎症傷害の処置および評価

Country Status (7)

Country Link
US (2) US20080187544A1 (cg-RX-API-DMAC7.html)
EP (1) EP1885388B1 (cg-RX-API-DMAC7.html)
JP (4) JP5339901B2 (cg-RX-API-DMAC7.html)
AU (1) AU2006244014B2 (cg-RX-API-DMAC7.html)
CA (1) CA2607697C (cg-RX-API-DMAC7.html)
ES (1) ES2432564T3 (cg-RX-API-DMAC7.html)
WO (1) WO2006122187A2 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
EA004590B1 (ru) 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
AU2003224950B2 (en) * 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006130374A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
SG182183A1 (en) 2007-06-08 2012-07-30 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
EP2545938A1 (en) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
BR112012032778A2 (pt) * 2010-06-24 2019-09-24 Abbvie Inc "proteínas multiespecíficas e multivalentes"
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
BR112013007293A2 (pt) 2010-10-05 2016-06-14 Hoffmann La Roche anticorpos contra a tweak de seres humanos e suas utilizações
RU2614257C2 (ru) * 2011-04-20 2017-03-24 Сандоз Аг СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
AU2012326170B2 (en) 2011-10-18 2016-12-22 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
KR101674784B1 (ko) 2012-04-05 2016-11-09 에프. 호프만-라 로슈 아게 인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
KR102250937B1 (ko) 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
JP2015061592A (ja) * 2013-08-21 2015-04-02 コニカミノルタ株式会社 超音波診断装置、超音波画像処理方法およびコンピュータ読み取り可能な非一時的な記録媒体
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
GB201501612D0 (en) * 2015-01-30 2015-03-18 Univ Birmingham Assay
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200313A (en) 1983-08-05 1993-04-06 Miles Inc. Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
US4777245A (en) 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
US4921698A (en) 1984-05-25 1990-05-01 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
AT396939B (de) 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
ATE354638T1 (de) 1994-12-13 2007-03-15 Human Genome Sciences Inc Menschlicher gewebsinhibitor von metalloproteinase-4
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
CA2262756C (en) 1996-08-07 2012-06-12 Biogen, Inc. A tumor necrosis factor related ligand
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US5858991A (en) 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
JP2001513626A (ja) * 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なtnfファミリーのメンバー
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
PT1015477E (pt) 1997-05-30 2010-12-28 Human Genome Sciences Inc 32 proteínas humanas segregadas
US7001992B2 (en) 1997-05-30 2006-02-21 Human Genome Sciences, Inc. Antibodies to secreted protein HEMCM42
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999014330A1 (en) 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
AU749948B2 (en) 1997-10-10 2002-07-04 Genentech Inc. APO-3 ligand
US20020072089A1 (en) 1999-11-23 2002-06-13 Holtzman Douglas A. Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
US6046381A (en) 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
WO1999059614A1 (en) 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing
EP1080194A2 (en) 1998-05-29 2001-03-07 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
IL142539A0 (en) 1998-10-16 2002-03-10 Immunex Corp Inhibitors of platelet activation and recruitment
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
IL143031A0 (en) 1998-12-22 2002-04-21 Genentech Inc Methods and compositions for inhibiting neoplastic cell growth
EA004590B1 (ru) * 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
PT1623990E (pt) 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
KR20050004240A (ko) 1999-08-31 2005-01-12 제넨테크, 인크. 종양 치료용 조성물 및 방법
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
CA2394015C (en) * 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
EP1908780B1 (en) 2000-01-03 2012-08-15 The Trustees Of The University Of Pennsylvania Novel chimeric proteins and methods for using the same
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
AU2001233034A1 (en) 2000-01-27 2001-08-07 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US7074408B2 (en) 2000-02-25 2006-07-11 Immunex Corporation Use of integrin antagonists to inhibit angiogenesis
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
US6943146B2 (en) * 2000-05-08 2005-09-13 Biogen Idec Ma Inc. Method for promoting neovascularization
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US20040047854A1 (en) 2001-07-27 2004-03-11 Black Roy A. Human disintegrin protein
AU8901901A (en) 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU1305302A (en) 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
EP1354950A4 (en) 2000-12-28 2005-01-12 Asahi Kasei Pharma Corp ACTIVATION GENE OF NF-KB
EP1423134A2 (en) 2001-03-21 2004-06-02 Human Genome Sciences Human secreted proteins
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
WO2002094864A2 (en) 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003040307A2 (en) 2001-07-27 2003-05-15 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
US20040091473A1 (en) 2001-07-27 2004-05-13 Dubose Robert F. Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
US20030148314A1 (en) 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2003070763A1 (en) 2001-08-16 2003-08-28 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
AU2003224950B2 (en) * 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
US7754884B2 (en) 2005-01-03 2010-07-13 Vanderbilt University Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004074433A2 (en) 2003-01-30 2004-09-02 Yale University Rag polypeptides, nucleic acids, and their use
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2004079014A2 (en) 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
JP4823060B2 (ja) 2003-07-24 2011-11-24 アムジェン インコーポレイテッド Tweak受容体のマルチマー化およびオリゴマー化可溶性断片に関する組成物および方法
EP1566636A1 (en) 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
EP1811838A4 (en) 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
AU2006214179A1 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
CN101171035A (zh) 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130374A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008048924A2 (en) 2006-10-16 2008-04-24 Biogen Idec Ma Inc. Biomarkers of multiple sclerosis
AU2009246640A1 (en) 2008-05-15 2009-11-19 Biogen Idec Ma Inc. Anti-Fn14 antibodies and uses thereof
WO2010085648A2 (en) 2009-01-23 2010-07-29 Linda Burkly C Methods for reducing radiation-induced tissue damage
MX2011007936A (es) 2009-01-30 2011-08-17 Biogen Idec Inc Metodos para regeneracion de tejido pancreatico.
BR112013007293A2 (pt) 2010-10-05 2016-06-14 Hoffmann La Roche anticorpos contra a tweak de seres humanos e suas utilizações

Similar Documents

Publication Publication Date Title
JP5339901B2 (ja) 炎症傷害の処置および評価
JP7106386B2 (ja) コロニー刺激因子1受容体(csf1r)を結合する抗体によって状態を治療する方法
EP3098238B1 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
JP6066912B2 (ja) Dkk1抗体およびその使用方法
AU2008266745B2 (en) Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
KR20220162819A (ko) 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
KR20130140230A (ko) Tweak 결합 항체
US20160340433A1 (en) Selection and treatment of subjects
US20200179486A1 (en) Method of treating pediatric disorders
TW202106712A (zh) 類風溼性關節炎之診斷及治療方法
JP2017520562A (ja) コロニー刺激因子1受容体(csf1r)に結合する抗体で疾患を治療する方法
AU2018238540B2 (en) Treatment of lupus using humanized anti-CXCR5 antibodies
HK1232230B (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same